deucravacitinib

Go or no go? Bristol’s Tyk2 test
EP Vantage
Wed, 08/31/22 - 10:15 am
FDA
Bristol Myers Squibb
deucravacitinib
Amylyx Pharmaceuticals
ALS
AMX0035
Ferring Pharmaceuticals
microbiome
RBX2660
Revance Therapeutics
Bluebird Bio
Spectrum Pharmaceuticals
JNJ
Oncopeptides
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Tue, 08/16/22 - 12:22 pm
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Fierce Biotech
Wed, 06/1/22 - 09:48 am
Bristol Myers Squibb
lupus
psoriasis
deucravacitinib
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Fierce Biotech
Thu, 05/12/22 - 10:48 am
Bristol Myers Squibb
deucravacitinib
clinical trials
psoriasis
Amgen
Otezla
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
Amgen builds Otezla’s psoriasis label as rival BMS looms large
Pharmaforum
Wed, 12/22/21 - 11:19 am
Amgen
Otezla
psoriasis
Bristol Myers Squibb
deucravacitinib
Amid JAK debacle, Bristol Myers settles in for FDA's long review of potential first TYK2 drug
Endpoints
Mon, 11/29/21 - 11:09 am
Bristol Myers Squibb
FDA
deucravacitinib
Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
Fierce Biotech
Tue, 11/2/21 - 11:55 pm
Pfizer
Tyk2
deucravacitinib
Bristol Myers Squibb
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Fierce Biotech
Thu, 10/7/21 - 11:24 am
Bristol Myers Squibb
deucravacitinib
Amgen
Otzela
psoriasis
ulcerative colitis
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Endpoints
Tue, 08/17/21 - 10:56 pm
Bristol Myers Squibb
Celgene
Nimbus Therapeutics
psoriasis
deucravacitinib
Bris­tol My­er­s' next-gen im­munol­o­gy med busts Am­gen's Ote­zla in head-to-head study. Is a show­down com­ing?
Endpoints
Fri, 04/23/21 - 11:12 am
Bristol Myers Squibb
biologics
psoriasis
Amgen
deucravacitinib
Otezla
Bristol Myers' psoriasis drug beats Amgen rival in phase 3
Fierce Biotech
Tue, 11/3/20 - 10:49 am
Bristol-Myers Squibb
deucravacitinib
Amgen
Otezla
clinial trials
plaque psoriasis